RT Journal Article
SR Electronic
T1 Observational Study of Metformin and Risk of Mortality in Patients Hospitalized with Covid-19
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.06.19.20135095
DO 10.1101/2020.06.19.20135095
A1 Bramante, Carolyn T.
A1 Ingraham, Nicholas E.
A1 Murray, Thomas A.
A1 Marmor, Schelomo
A1 Hovertsen, Shane
A1 Gronski, Jessica
A1 McNeil, Chace
A1 Feng, Ruoying
A1 Guzman, Gabriel
A1 Abdelwahab, Nermine
A1 King, Samantha
A1 Meehan, Thomas
A1 Pendleton, Kathryn M.
A1 Benson, Bradley
A1 Vojta, Deneen
A1 Tignanelli, Christopher J.
YR 2020
UL http://medrxiv.org/content/early/2020/06/28/2020.06.19.20135095.abstract
AB Importance Type 2 diabetes (T2DM) and obesity are significant risk factors for mortality in Covid19. Metformin has sex specific immunomodulatory effects which may elucidate treatment mechanisms in COVID-19. Objective: We sought to identify whether metformin reduced mortality from Covid19 and if sex specific interactions exist.Design Retrospective review of de-identified claims from UnitedHealth Group’s Clinical Discovery Database. Unadjusted and multivariate models were conducted to assess risk of mortality based on metformin and tumor necrosis factor alpha (TNFα) inhibitors as home medications in individuals with T2DM and obesity, controlling for comorbidities, medications, demographics, and state. Heterogeneity of effect was assessed by sex.Setting The database includes all 50 states in the United States. Participants: Persons with at least 6 months of continuous coverage from UnitedHealth Group in 2019 who were hospitalized with Covid-19. Persons in the metformin group had > 90 days of metformin claims in the 12 months before hospitalization.Results 6,256 persons were included; 52.8% female; mean age 75 years. Metformin was associated with decreased mortality in women by logistic regression, OR 0.792 (0.640, 0.979); mixed effects OR 0.780 (0.631, 0.965); Cox proportional-hazards: HR 0.785 (0.650, 0.951); and propensity matching, OR of 0.759 (0.601, 0.960). There was no significant reduction in mortality among men. TNFα inhibitors were associated with decreased mortality, by propensity matching in a limited model, OR 0.19 (0.0378, 0.983).Conclusions Metformin was significantly associated with reduced mortality in women with obesity or T2DM in observational analyses of claims data from individuals hospitalized with Covid-19. This sex-specific finding is consistent with metformin’s reduction of TNFα in females over males, and suggests that metformin conveys protection in Covid-19 through TNFα effects. Prospective studies are needed to understand mechanism and causality.Question Metformin has many anti-inflammatory effects, including sex-specific effects on TNFα. Is metformin protective from the Sars-CoV-2 virus, and does the effect differ by sex?Findings Metformin was associated with reduced mortality in women who were hospitalized with Covid-19, but not in men who were hospitalized with Covid-19.Meaning The sex-dependent survival by metformin use points towards TNFα reduction as a key mechanism for protection from Covid-19.Competing Interest StatementThe authors have declared no competing interest.Funding Statement1.This research was supported by the National Heart, Lung, Blood Institute T32HL07741 (NEI) 2.This research was supported by the Agency for Healthcare Research and Quality (AHRQ) and Patient-Centered Outcomes Research Institute (PCORI), grant K12HS026379 (CJT) 3.This research was supposed by the Minnesota Learning Health System Mentored Training Program (MH-LHS), M Health Fairview Institutional Funds (CTB). 4.This research was supported by the National Center for Advancing Translational Sciences, grants KL2TR002492 and UL1TR002494 (CTB) 5.This research was supported by the National Cancer Institute (NCI), grant P30CA077598.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the University of Minnesota institutional review board (STUDY00001489) which provided a waiver of consent for this study.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe senior author has had access to the data for the entirety of the research process and analyses. The first author has had access to all of the data analyses.